ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2025
Activation of Hippocampal ACE2 Prevents the Dysbiosis-induced Depression-like Behavior in Mice by Enhanced Neurogenesis and Neuroprotection via Mas Receptor.
Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The nonpeptide angiotensin-(1-7) mimic AVE0991 attenuates neuroendocrine and behavioral responses to chronic unpredictable stress.Psychopharmacology · 2026Article
- SirT2 Inhibition is Associated with Improvements in Depression-like Behavior and Memory Impairment in Olfactory Bulbectomized Mice.Molecular neurobiology · 2026Article
- Microglial activation and RAS signaling: a dual-edged sword in neuroinflammation.American journal of physiology. Regulatory, integrative and comparative physiology · 2026Review
- Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The association between gut microbiota imbalance and depression is well known; however, its underlying mechanisms remain unclear. Angiotensin (Ang)-converting enzyme 2 (ACE2) transforms Ang II into Ang (1-7), which exerts antidepressant effects via the Mas receptor (MasR). However, the role of ACE2 in dysbiosis-related depression in the brain remains unclear. In this study, we assessed changes in brain ACE2 expression and whether diminazene aceturate (DIZE), an ACE2 activator, alleviates depression-like behavior in an antibiotic-induced (ABX) dysbiosis mouse model. The tail suspension test revealed depression-like behavior in ABX mice. Western blotting and immunohistochemistry revealed decreased expression levels of ACE2, Ang (1-7), p-CAMKII, p-CREB, BDNF, synaptophysin, p-PPARγ, CD206, TREM2, and IL-10 and reduced neurogenesis in the dentate gyrus of the hippocampus. Iba1, CD86, iNOS, IL-1β, TNF-α, and cleaved caspase-3 levels were increased, indicating microglial activation in the hippocampus. MasR staining was observed in neurons and microglia in the hippocampus of ABX mice. Furthermore, p-CAMKII and p-CREB staining was observed in neurons, while p-PPARγ staining was observed in microglia in the hippocampus of ABX mice treated with DIZE. DIZE administration prevented ABX-induced changes, whereas the effects of DIZE were abolished by co-administration with A779, a MasR inhibitor. These findings suggest that hippocampal ACE2 expression plays a crucial role in dysbiosis-related depression associated with gut microbiota imbalance, potentially offering a target for therapeutic interventions.
Indexed as
Identifiers
40679669What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.